26625
document
Intermittent recombinant growth hormone treatment in short children born small for gestational age : four-year results of a randomized trial of two different treatment regimens . BACKGROUND Treatment of short children born small for gestational age SGA with recombinant human growth hormone r-hGH increases growth velocity during childhood . As in other indications , the growth velocity in these patients is more marked during the first year of treatment and then decreases . This study was undertaken to evaluate the efficacy of different r-hGH treatment schedules ( 67 microg/kg/day in a discontinuous or continuous regimen ) during the second year of r-hGH treatment by comparing height velocity changes and total gain of height over a 4-year period . METHODS 58 growth-retarded SGA children aged 2-5 years were randomized to a TOTO regimen ( 4 years alternating treatment ( T ) and observation ( O ) , n = 30 ) or a TTOO regimen ( 2 years ' treatment , followed by 2 years ' observation , n = 28 ) . Height velocity HV and total height gain were assessed during the 4-year study . RESULTS In both groups , HV and HV standard deviation score HV-SDSCA increased during treatment and decreased during observation periods . Interruption of treatment in the TOTO group did not result in a better gain in height standard deviation score H-SDSCA when compared with the TTOO group . After 4 years of study , the gain in H-SDSCA was 1.4 + or - 01 in the TOTO group and 1.6 + or - 0.2 in the TTOO group leading to a mean height of -2.0 + or - 1.0 SDS and -2.0 + or - 0.8 SDS , respectively . The rate of bone maturation was similar in the two groups . CONCLUSIONS In short SGA children , TOTO and TTOO regimens produced significant improvements in growth during r-hGH treatment . However , treatment interruption after 1 year did not influence the overall gain in height SDS when compared with 2 years ' continuous treatment .
26626
Intervention_Psychological
Intermittent recombinant growth hormone treatment
26627
Intervention_Pharmacological
recombinant human growth hormone r-hGH
26628
Intervention_Pharmacological
TOTO regimen
26629
Intervention_Pharmacological
TOTO
26630
Intervention_Pharmacological
TTOO
26631
Intervention_Psychological
r-hGH treatment
26632
Outcome_Physical
growth velocity
26633
Outcome_Physical
growth velocity
26634
Outcome_Physical
height velocity
26635
Outcome_Physical
total gain of height
26636
Outcome_Physical
Height velocity HV
26637
Outcome_Physical
total height gain
26638
Outcome_Physical
HV
26639
Outcome_Physical
HV standard deviation score HV-SDSCA
26640
Outcome_Physical
gain in height standard deviation score H-SDSCA
26641
Outcome_Physical
gain in H-SDSCA
26642
Outcome_Physical
height
26643
Outcome_Physical
rate of bone maturation
26644
Outcome_Physical
growth
26645
Outcome_Physical
overall gain in height SDS
26646
Participant_Age
short children born small for gestational age :
26647
Participant_Age
short children born small for gestational age SGA
26648
Participant_Sample-size
58
26649
Participant_Age
growth-retarded SGA children aged 2-5 years were randomized